SCHEMBL2430002

SCHEMBL2430002

Brc1ccc2sc(-c3ccc(-c4cnco4)cc3)nc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.56
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
APP P05067 5/20 0.47
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
NFKB1 P19838 1/20 0.44
RAB9A P51151 1/20 0.44
GFER P55789 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
NOTUM Q6P988 1/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
HDAC6 Q9UBN7 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2431811 0.90 APP (0.60) GAAMEN1KMT2AAPPMAPT
SCHEMBL2433296 0.84 KDM4E (0.44) GAAMEN1KMT2AAPPMAPT
SCHEMBL10989659 0.81 APP (0.61) GAAMEN1KMT2AAPPMAPT
SCHEMBL2435129 0.76 APP (0.56) GAAAPPMAPTKDM4ENPC1
SCHEMBL19984988 0.76 APP (0.77) GAAMEN1KMT2AAPPMAPT
SCHEMBL25752044 0.76 APP (0.55) GAAMEN1KMT2AAPPMAPT
SCHEMBL2430009 0.76 CYP3A4 (0.44) GAAMEN1KMT2AAPPMAPT
SCHEMBL595453 0.75 KDM4E (0.57) GAAMEN1KMT2AAPPMAPT
SCHEMBL102644 0.74 GAA (1.00) GAAMEN1KMT2AKDM4ENPC1
SCHEMBL6608660 0.73 GAA (0.96) GAAMEN1KMT2AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 EP disclosed
US-8022075-B2 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition FUJIFILM RI PHARMA CO., LTD. (JP) 2011-09-20 US disclosed
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO., LTD. (JP) 2009-06-25 US disclosed
EP-1956013-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION Fujifilm RI Pharma Co., Ltd. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION APP, TTR, BACE1 GAA 452/4885MEN1 609/4885KMT2A 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.